Ahmed Glaucoma Valve Alone, With Amniotic Membrane or With Mitomycin C (MMC) for Treatment of Refractory Glaucoma

Shahid Beheshti University of Medical Sciences

Status and phase: Unknown; Phase 1

Conditions: Refractory Glaucoma

Treatments: Procedure: amniotic membrane coverage; Device: Ahmed Glaucoma Valve (AGV); Drug: Mitomycin C (MMC)

Study type: Interventional

Funder types: Other

Identifiers

NCT00893490

8756

Details and patient eligibility

About

This randomized, controlled trial (RCT) compares the efficacy and safety of Ahmed Glaucoma Valve (AGV) implantation alone, with 3 minutes MMC application or with a single layer coverage of amniotic membrane. Outcomes include intraocular eye pressure (IOP), postoperative glaucoma medication and complications. AGV implantation site will be superior or inferior based on indication and these groups will be randomized separately.

Sex: All

Ages: 7 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients with refractory glaucoma

Exclusion criteria

• children under 7 years old
• adults above 75 years old
• uncooperative patients
• patients underwent the operation for second time
• patients with major operation with AGV

Trial design

0 participants in 3 patient groups

Ahmed Glaucoma Valve (AGV) alone

Experimental group

Treatment:

Device: Ahmed Glaucoma Valve (AGV)

AGV plus MMC

Experimental group

Treatment:

Drug: Mitomycin C (MMC)

Device: Ahmed Glaucoma Valve (AGV)

AGV plus amniotic membrane coverage

Experimental group

Treatment:

Procedure: amniotic membrane coverage

Device: Ahmed Glaucoma Valve (AGV)